GlassScriptPhysician profile
Scott J Jones
NPI 1619918703
$10,109.57
in general payments reported to CMS, 2019-2025
54 companies · $1,476 in 2025
The $1,476 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,188 · 2020: $718 · 2021: $1,470 · 2022: $1,390 · 2023: $1,812 · 2024: $2,056 · 2025: $1,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,343.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,588.16 | 2019-2025 | |
| Novo Nordisk INC | $936.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $684.76 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $639.52 | 2019-2021 | |
| Pfizer INC. | $588.45 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $586.42 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $542.25 | 2019-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $526.83 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $344.14 | 2020-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $295.26 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $274.87 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $265.57 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $222.55 | 2019-2023 | Spravato |
| Otsuka America Pharmaceutical, INC. | $198.57 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $172.09 | 2023-2025 | Cologuard Collection Kit |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.